Abstract:Ethnopharmacological relevance: Bullatine A, a C-20-diterpenoid alkaloid and one of the major effective ingredients in Aconiti brachypodi Radix (Xue-shang-yi-zhi-hao), can block pain hypersensitivity in a variety of rodent models through expression of spinal microglial dynorphin A.Aim of the study: To assess the interaction between bullatine A and morphine on antinociception in acute nociception and pain hypersensitivity states, with the exogenous synthetic dynorphin A as a comparisonMaterials and methods: Spinal nerve ligation-induced neuropathic rats and naive mice were used for assessing the acute and chronic interactions of bullatine A/dynorphin A with morphine.Results: Single subcutaneous injection of bullatine A or dynorphin A(1-17) did not either alter formalin- and thermally (hot-plate and water immersion tests)-induced acute nociception or potentiate morphine antinociception in naive mice. In contrast, bullatine A dose-dependently inhibited formalin-induced tonic pain with the efficacy of 54% inhibition and the half-effective dose of 0.9 mg/kg. Concurrent bullatine A additively enhanced morphine antinociception. In neuropathic rats, the antinociceptive effects of multiple bidaily intrathecal injections of bullatine A and dynorphin A remained consistent over 13 days, whereas morphine produced progressive and complete tolerance to antinociception, which was completely inhibited by concurrent bullatine A and dynorphin A. A single intrathecal injection of bullatine A and dynorphin A immediately reversed established morphine tolerance in neuropathic rats, although the blockade was a less degree in the thermally induced mouse acute nociceptive tests. The inhibitory effects of bullatine A and dynorphin A on morphine tolerance were immediately and completely attenuated by intrathecal dynorphin A antibody and/or selective kappa-opioid receptor antagonist GNTI.Conclusion: These results suggest that bullatine A produces antinociception without induction of tolerance and inhibits morphine antinociceptive tolerance, and provide pharmacological basis for concurrent bullatine A and morphine treatment for chronic pain and morphine analgesic tolerance.

Bulleyaconitine A Inhibits Morphine-Induced Withdrawal Symptoms, Conditioned Place Preference, and Locomotor Sensitization Via Microglial Dynorphin A Expression

Bulleyaconitine A inhibits morphine physical and psychological dependence via dynorphin A expression

Aconitum-Derived Bulleyaconitine A Exhibits Antihypersensitivity Through Direct Stimulating Dynorphin A Expression in Spinal Microglia

Aconitum-derived bulleyaconitine A exhibits anti-hypersensitivity through direct stimulating dynorphin A expression in spinal microglia.

Bulleyaconitine A Inhibits Visceral Nociception and Spinal Synaptic Plasticity through Stimulation of Microglial Release of Dynorphin A

Oral application of bulleyaconitine A attenuates morphine tolerance in neuropathic rats by inhibiting long-term potentiation at C-fiber synapses and protein kinase C gamma in spinal dorsal horn

Molecular Signaling Underlying Bulleyaconitine A (Baa)-Induced Microglial Expression of Prodynorphin

Concurrent Bullatine A Enhances Morphine Antinociception and Inhibits Morphine Antinociceptive Tolerance by Indirect Activation of Spinal Κ-Opioid Receptors.

Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats

Behavioral and cellular pharmacology characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) as a mu opioid receptor selective ligand.

Effects of Total Alkaloids of Aconitum Sungpanens Hand-Mazz on Morphine-Induced Behavioral Senitization and Withdrawal Sympotoms of Morphine-Dependence

Bulleyaconitine A Exerts Antianxiety and Antivisceral Hypersensitivity Effects.

Interactions of the potent D-amino acid oxidase inhibitor CBIO with morphine in pain and tolerance to analgesia.

BDNF-AAV has protective effects on morphine-induced conditioned place preference through BDNF, TrkB, and CREB concentration changes in the VTA and NAc

Negative allosteric modulation of CB1 cannabinoid receptor signaling decreases intravenous morphine self-administration and relapse in mice

Ionotropic Glutamatergic Neurotransmission in the Ventral Tegmental Area Modulates ΔFosB Expression in the Nucleus Accumbens and Abstinence Syndrome in Morphine Withdrawal Rats

A New Buprenorphine Analogy, Thenorphine,inhibits Morphine-Induced Behavioral Sensitization in Mice

Effect of NR2B Antisense Oligonucleotide on Naloxone-Induced Withdrawal Responses in Morphine-Dependent Rats

Effects of Brain-Derived Neurotrophic Factor and Adeno-Associated Viral Vector on Morphine-Induced Condition Through Target Concentration Changes in the Ventral Tegmental Area and Nucleus Accumbens

An-jun-ning, a Traditional Herbal Formula, Attenuates Spontaneous Withdrawal Symptoms Via Modulation of the Dopamine System in Morphine-Dependent Rats

The Possible Involvement of Endogenous Ligands for Mu-, Delta- and Kappa-Opioid Receptors in Modulating Morphine-Induced CPP Expression in Rats